

PRESS RELEASE

19 March 2025 16:20:00 CET

Saniona's CEO, Thomas Feldthus, participates in Redeye's Commercialization-in-Life-Science event on March 20, 2025

Saniona, a clinical-stage biopharmaceutical company, announces that the company's CEO, Thomas Feldthus, will participate at Redeye's theme event, Commercialization in Life Science, on March 20 at 9:30 am CET.

The event will be live broadcasted at Events - Redeye.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: TesometTM, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

Attachments

Saniona's CEO, Thomas Feldthus, participates in Redeye's Commercialization-in-Life-Science event on March 20, 2025